Wolfe Research Increases Gilead Sciences (NASDAQ:GILD) Price Target to $155.00

Gilead Sciences (NASDAQ:GILD) had its price objective hoisted by stock analysts at Wolfe Research from $150.00 to $155.00 in a research note issued to investors on Wednesday,MarketScreener reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Wolfe Research’s price objective points to a potential upside of 11.07% from the stock’s current price.

Other research analysts have also issued reports about the company. Truist Financial upped their price objective on Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. BMO Capital Markets upped their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday. Needham & Company LLC lifted their price objective on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Argus boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, Daiwa Capital Markets raised their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $135.56.

Gilead Sciences Stock Down 0.1%

Gilead Sciences stock opened at $139.55 on Wednesday. The company’s 50-day moving average price is $125.05 and its two-hundred day moving average price is $119.38. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock has a market cap of $173.14 billion, a P/E ratio of 21.64, a P/E/G ratio of 0.73 and a beta of 0.33. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $141.71.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.02 earnings per share. As a group, analysts expect that Gilead Sciences will post 7.95 EPS for the current year.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 257,397 shares of company stock worth $33,385,512. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in GILD. GoalVest Advisory LLC lifted its stake in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new position in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at $27,000. Financial Consulate Inc. grew its position in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the last quarter. Finally, Putney Financial Group LLC increased its holdings in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wolfe Research raised its price target to $155 (from $150) and kept an “outperform” rating — implying ~10% upside from current levels. Wolfe Research PT Raise
• Positive Sentiment: Citigroup published a bullish forecast for strong price appreciation, supporting demand expectations for GILD. Citigroup Forecast
• Positive Sentiment: Truist Financial also issued a forecast calling for meaningful upside, lining up with broader analyst optimism. Truist Forecast
• Positive Sentiment: BMO Capital Markets added to the chorus of bullish forecasts, which reinforces analyst-driven buying interest. BMO Forecast
• Positive Sentiment: UBS reiterated expectations for upside, further supporting consensus that GILD’s fundamentals and pipeline justify higher valuations. UBS Note
• Positive Sentiment: Coverage pieces (BarChart, Zacks interest) note that Gilead has outperformed the market and that analysts are broadly optimistic — positive sentiment that can attract momentum flows. BarChart Analysts Overview
• Neutral Sentiment: Zacks flagged increased investor attention to GILD (tracking user searches), which can boost volume but is not a directional catalyst by itself. Zacks Attention Note
• Neutral Sentiment: Reported short-interest data is inconsistent (entries show increases but list 0 shares / NaN), suggesting a data glitch — no clear short-squeeze or heavy shorting signal from this report.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares at ~$139.89 (≈$1.4M), trimming his holding ~1.76%. Insider sales can be read negatively by some investors even if part of routine diversification. SEC Form 4

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.